Profound Medical welcomes Dr. Cynthia Lavoie to its Board of Directors

– CANADA, Mississauga –  Profound Medical Corp. (NASDAQ: PROF | TSX: PRN), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the appointment of Dr. Cynthia Lavoie Ph.D., to its Board of Directors.

“We are delighted to welcome Cynthia to our Board,” said CEO and Chairman, Arun Menawat. “She brings a deep understanding of our business, a strong record of academic and scientific accomplishment, an extensive industry and investment community network, and a breadth of corporate governance experience. This unique combination will be a tremendous asset as Profound continues to execute its growth strategy.”

About Dr. Cythia Lavoie

A seasoned healthcare investment professional with 18 years of experience in venture capital, Dr. Lavoie’s expertise includes creating companies de novo and leading investments into businesses developing therapeutics, devices, and diagnostic tools. Dr. Lavoie is currently President and Managing Director of AllosteRx Capital Management. She also serves as President and Chief Investment Officer of CCRM Enterprises Inc.

Prior to co-founding AllosteRx, she was a General Partner with TVM Life Science Management Inc. a global venture capital group with main offices in Munich and Montreal. She was recruited to TVM from VG Partners Inc., where she was a Partner and co-headed its life sciences fund. Before joining the investment community, Dr. Lavoie served in a variety of academic and scientific leadership positions for 10 years, working with research institutes and life science companies.

Dr. Lavoie holds an MBA from the Rotman School of Management at the University of Toronto and earned her Ph.D. in Molecular Biology from McGill University. She has previously served on the boards of 15 companies developing products ranging from the early- to revenue-generating stages.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration.

Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

For more information : https://profoundmedical.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team